ReviewTherapeutic advances in medical oncology2018

CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.

Adriana Matutino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.